Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684661 | 0.93 | HRH3 (0.37) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL818581 | 0.87 | CHRNB2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3646231 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3640335 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4228795 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1296457 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10210925 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20128072 | 0.80 | CHRNB2 (0.40) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1296976 | 0.80 | HRH3 (0.41) | BTKMAPK1HRH3CHRM2CHRM3 | |
| SCHEMBL6159675 | 0.79 | DGAT1 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-10-03 | — | — | US | disclosed |
| WO-2018089402-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-05-10 | — | — | US | disclosed |
| WO-2018071620-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435369-B2 | Tricyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | SMN1; SMN2 2018/4885CHRNB2 936/4885CHRNA4 865/4885 |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | SMN1; SMN2 1501/4885CHRNB2 942/4885CHRNA4 966/4885 |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | SMN1; SMN2 1501/4885CHRNB2 942/4885CHRNA4 966/4885 |
| US-20180127368-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | SMN1; SMN2 2018/4885CHRNB2 936/4885CHRNA4 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.